New drug HSK56630 tested in humans for first time

NCT ID NCT07580794

Recruiting now Knowledge-focused Sponsor: Haisco Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests the safety and tolerability of a new drug called HSK56630 in 40 healthy adults. Participants receive a single dose of the drug or a placebo, and researchers monitor for side effects and how the drug moves through the body. No therapeutic benefit is expected; the goal is to gather initial safety data before further studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

HSK56630

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Veritus Research Pty Ltd
RECRUITING

Bayswater, Victoria, 3153, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••